title: COX-2 has a critical role during incorporation of structural bone allografts.
abstract: Nonsteroidal anti-inflammatory drugs (NSAIDs), which inhibit cyclooxygenase (COX) activity, reduced pain and are commonly used in patients with skeletal injury. In this article we will also present data to show that selective COX-2 inhibitor delays allograft healing and incorporation. In contrast, local delivery of prostaglandin E2 (PGE2) enhanced bone formation at cortical bone graft junction. A 4-mm mid-diaphyseal segmental femoral defect was created and then repaired by frozen bone allograft of the same size. A 22-gauge metal pin was placed in the intramedullary cavity to stabilize the bone graft. Healing was evaluated weekly by X ray and by a semiquantitative histomorphometric analysis at 5 weeks postsurgery. Celecoxib (25 mg/kg/day) and Ketorolac (4 mg/kg/day) were administered daily for 2 weeks or 5 weeks. PGE2 was infused locally at a dose of 800 nmol/kg per day via osmotic minipump for 4 weeks. Inhibition of cyclooxygenase by daily administration of the Celecoxib or Ketorolac for 5 weeks reduced new bone ingrowth by about 60% (P < 0.05). The percentage of bony bridging in both drug-treated groups was significantly decreased at 5 weeks. Temporal administration of Celecoxib for 2 weeks also significantly reduced bone formation by 45% and withdrawal of the Celecoxib only led to slight recovery of bone formation at the graft side. In contrast to the inhibitory effects of NSAIDS, PGE2 infusion at the cortical bone junction increased bone formation by about twofold. These results demonstrated that COX-2 is essential for bone allograft incorporation. Furthermore, our data support the notion that COX-2-dependent PGE2 produced at the early stage of bone healing is prerequisite for efficient skeletal repair.
authors.affiliation: Department of Orthopedics, The Center for Musculoskeletal Research, University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, NY 14642, USA. Regis_OKeefe@URMC.rochester.edu
authors.forename: Regis J
authors.initials: RJ
authors.lastname: O'Keefe
authors.forename: Prarop
authors.initials: P
authors.lastname: Tiyapatanaputi
authors.forename: Chao
authors.initials: C
authors.lastname: Xie
authors.forename: Tian Fang
authors.initials: TF
authors.lastname: Li
authors.forename: Chris
authors.initials: C
authors.lastname: Clark
authors.forename: Micheal J
authors.initials: MJ
authors.lastname: Zuscik
authors.forename: Di
authors.initials: D
authors.lastname: Chen
authors.forename: Hicham
authors.initials: H
authors.lastname: Drissi
authors.forename: Edward
authors.initials: E
authors.lastname: Schwarz
authors.forename: Xinping
authors.initials: X
authors.lastname: Zhang
mesh_terms: D000818:Animals; D016025:Bone Transplantation / Q000502:physiology*; D051546:Cyclooxygenase 2 / Q000378:metabolism*; D004195:Disease Models, Animal; D005269:Femur / Q000201:enzymology; D006801:Humans; D051379:Mice; D008810:Mice, Inbred C57BL; D014184:Transplantation, Homologous
chemical_list: D051546:Cyclooxygenase 2